Mico BioMed Co. Ltd. (214610) - Total Assets
Based on the latest financial reports, Mico BioMed Co. Ltd. (214610) holds total assets worth ₩33.69 Billion KRW (≈ $22.83 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Mico BioMed Co. Ltd. total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Mico BioMed Co. Ltd. - Total Assets Trend (2015–2024)
This chart illustrates how Mico BioMed Co. Ltd.'s total assets have evolved over time, based on quarterly financial data. Check Mico BioMed Co. Ltd. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Mico BioMed Co. Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Mico BioMed Co. Ltd.'s total assets of ₩33.69 Billion consist of 49.0% current assets and 51.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩13.67 Billion | 25.1% |
| Accounts Receivable | ₩984.30 Million | 1.8% |
| Inventory | ₩6.97 Billion | 12.8% |
| Property, Plant & Equipment | ₩20.24 Billion | 37.2% |
| Intangible Assets | ₩15.92 Million | 0.0% |
| Goodwill | ₩6.50 Billion | 11.9% |
Asset Composition Trend (2015–2024)
This chart illustrates how Mico BioMed Co. Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Mico BioMed Co. Ltd. (214610) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mico BioMed Co. Ltd.'s current assets represent 49.0% of total assets in 2024, a decrease from 56.4% in 2015.
- Cash Position: Cash and equivalents constituted 25.1% of total assets in 2024, up from 1.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 37.2% of total assets.
Mico BioMed Co. Ltd. Competitors by Total Assets
Key competitors of Mico BioMed Co. Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GUOMAI Culture & Media Co. Ltd.
SHE:301052
|
China | CN¥852.81 Million |
|
Dogan Burda Dergi Yayincilik ve Pazarlama AS
IS:DOBUR
|
Turkey | TL352.39 Million |
|
Aspermont Ltd
AU:ASP
|
Australia | AU$15.32 Million |
|
Roularta
BR:ROU
|
Belgium | €319.32 Million |
|
Yellow Pages Limited
TO:Y
|
Canada | CA$162.59 Million |
|
Postmedia Network Canada Corp
TO:PNC-B
|
Canada | CA$134.18 Million |
|
Postmedia Network Canada Corp
TO:PNC-A
|
Canada | CA$134.18 Million |
|
COL Digital Publishing Group Co Ltd
SHE:300364
|
China | CN¥1.42 Billion |
Mico BioMed Co. Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.88 | 1.38 | 6.46 |
| Quick Ratio | 3.63 | 0.83 | 4.26 |
| Cash Ratio | 0.00 | 0.25 | 0.00 |
| Working Capital | ₩16.30 Billion | ₩6.14 Billion | ₩48.44 Billion |
Mico BioMed Co. Ltd. - Advanced Valuation Insights
This section examines the relationship between Mico BioMed Co. Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.09 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -11.2% |
| Total Assets | ₩54.47 Billion |
| Market Capitalization | $13.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values Mico BioMed Co. Ltd.'s assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Mico BioMed Co. Ltd.'s assets decreased by 11.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Mico BioMed Co. Ltd. (2015–2024)
The table below shows the annual total assets of Mico BioMed Co. Ltd. from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩54.47 Billion ≈ $36.91 Million |
-11.17% |
| 2023-12-31 | ₩61.32 Billion ≈ $41.55 Million |
+6.62% |
| 2022-12-31 | ₩57.51 Billion ≈ $38.97 Million |
-35.14% |
| 2021-12-31 | ₩88.68 Billion ≈ $60.10 Million |
+24.97% |
| 2020-12-31 | ₩70.96 Billion ≈ $48.09 Million |
+183.49% |
| 2019-12-31 | ₩25.03 Billion ≈ $16.96 Million |
+3.61% |
| 2018-12-31 | ₩24.16 Billion ≈ $16.37 Million |
+46.93% |
| 2017-12-31 | ₩16.44 Billion ≈ $11.14 Million |
+73.45% |
| 2016-12-31 | ₩9.48 Billion ≈ $6.42 Million |
-9.84% |
| 2015-12-31 | ₩10.51 Billion ≈ $7.13 Million |
-- |
About Mico BioMed Co. Ltd.
RollingStone Co., Ltd. provides point-of-care-testing diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real… Read more